SOLARA ACTIVE PHA SCI LTD
SOLARA · Pharma · NSE
₹478
Current Market Price
Fair Value (DCF)
₹987
Margin of Safety
+106.8%
Updated 2h ago
YieldIQ Score
75/100
Piotroski F-Score
9/9
Economic Moat
Narrow
Confidence
41%
ROE
—
Debt/Equity
0.51
WACC
9.7%
Market Cap
₹1,727 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
8.2%
Return on capital employed
EV / EBITDA
16.2×
Enterprise multiple
Debt / EBITDA
4.7×
Leverage vs earnings
Interest Coverage
1.0×
EBIT covers interest
Current Ratio
0.77×
Short-term liquidity
Asset Turnover
0.56×
Revenue per ₹ of assets
Revenue CAGR (3Y)
0.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹477.5
Bear case
₹552.37
MoS +13.6%
Base case
₹987.34
MoS +51.6%
Bull case
₹1,411.81
MoS +66.2%
Ratio Trends
SOLARA · last 7 annual periods
ROE
0.0%
ROCE
10.8%
Operating Margin
—
Debt / Equity
0.73×
PE
315.0×
EV / EBITDA
13.0×
Historical Financials
SOLARA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1617 Cr | ₹1268 Cr | ₹381 Cr | ₹299 Cr | ₹1241 Cr | -6.4% |
| EBITDA | — | ₹88.5 Cr | ₹150 Cr | ₹-285 Cr | ₹205 Cr | +23.4% |
| EBIT | ₹306 Cr | ₹-16.4 Cr | ₹27.0 Cr | ₹-136 Cr | — | — |
| PAT | ₹221 Cr | ₹-58.6 Cr | ₹3.8 Cr | ₹-255 Cr | ₹0.5 Cr | -77.8% |
| EPS (diluted) | ₹64.52 | ₹-16.29 | ₹1.05 | ₹-70.93 | — | — |
| CFO | ₹155 Cr | ₹-242 Cr | ₹156 Cr | ₹109 Cr | ₹213 Cr | +8.2% |
| CapEx | — | — | — | — | ₹-39.9 Cr | — |
| FCF | — | — | — | — | ₹173 Cr | +0.0% |
| Total Assets | — | ₹2945 Cr | ₹2899 Cr | ₹2351 Cr | ₹2232 Cr | -6.7% |
| Total Debt | — | — | ₹766 Cr | ₹894 Cr | ₹796 Cr | +1.0% |
| Shareholders' Equity | — | — | ₹1500 Cr | ₹934 Cr | ₹1097 Cr | -7.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SOLARA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| HIKAL HIKAL | — | — | Pending | 7.2% | — |
| UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
| MOREPENLAB MOREPENLAB | — | — | Pending | 9.9% | — |
| IOLCP IOLCP | — | — | Pending | 6.0% | — |
| BLISSGVS BLISS GVS PHARMA LTD | -46.4% | 22 | Overvalued | 7.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SOLARA in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. SOLARA ACTIVE PHA SCI LTD (SOLARA.NS) trades at 477.50 vs a model fair value of 987.34, a gap of 106.8%. Piotroski F-score: 9/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SOLARA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SOLARA →
Compare
Head-to-head with peers
Compare SOLARA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SOLARANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.